米国時間5月30日より米国臨床腫瘍学会（American Society of Clinical Oncology: ASCO）が開催されています。弊社サイニクス株式会社のパートナーであるOracle Life Sciencesのオンコロジースペシャリストおよび弊社 オンコロジーマーケットアセスメントチームが注目しているASCO 2025トピックをお届けします。

なお、Oracle Life Sciencesと共催で『最新のオンコロジー学会からみる薬剤開発と治療展望 -Evolving Trends in Oncology』セミナーを開催します（7/30・31 13:00～ / オンライン）。ASCOや、欧州臨床腫瘍学会（European Society for Medical Oncology：ESMO）、米国癌学会（American Association for Cancer Research: AACR）など最新学会の発表内容を踏まえ、今日のアンメットメディカルニーズ(UMNs)、臨床的意義と市場性の観点から注目される開発、治療展望について、最旬の7つの切り口でオンコロジースペシャリストが解説します。詳細は以下よりご確認いただけます。ぜひ皆様奮ってご参加ください。

7つの切り口から解説

ASCO 2025の注目トピック

胃がん・食道胃接合部がん (周術期)　/ MATTERHORN試験

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
6月1日（日）
Abstract LBA5 (Plenary)

HR+HER2-乳がん (1stライン) / SERENA-6試験

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
6月1日（日）
Abstract LBA4 (Plenary)

真性多血症(PV) / VERIFY試験

Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)
6月1日（日）
Abstract LBA3 (Plenary)

頭頸部がん (術後補助療法) / NIVOPOSTOP試験

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse
6月1日（日）
Abstract LBA2 (Plenary)

大腸がん (術後補助療法) / ATOMIC試験

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
6月1日（日）
Abstract LBA1 (Plenary)

HER2+乳がん (1stライン) / DESTINY-Breast09試験

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09
6月2日（月）
Abstract LBA1008 (Special LBA session)

トリプルネガティブ乳がん (1stライン) / ASCENT-04 試験 & KEYNOTE-D19試験

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
5月31日（土）
Abstract LBA109 (Breast Oral)

HR+HER2-乳がん (2ndライン＋)　/ VERITAC-2試験

Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
5月31日（土）
Abstract LBA1000 (Breast Oral)

HR+乳がん / INAVO120試験

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
5月31日（土）
Abstract 1003 (Breast Oral)

胃がん・胃食道接合部がん (2ndライン) / DESTINY-Gastric04試験

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study
5月31日（土）
Abstract LBA4002 (GI Oral)

膵臓がん (1stライン) / PANOVA-3試験

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)
5月31日（土）
Abstract LBA4005 (GI Oral)

食道がん・胃食道接合部がん (術後補助化学療法) / CheckMate 577試験

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577
5月31日（土）
Abstract 4000 (GI Oral)

転移性去勢感受性前立腺がん / AMPLITUDE試験

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
6月3日（火）
Abstract LBA5006 (GU Oral)

非転移性去勢感受性前立腺がん / PrTK03試験

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer
6月3日（火）
Abstract 5000 (GU Oral)

卵巣がん (2ndライン) / ROSELLA試験

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)
6月2日（月）
Abstract LBA5507 (Gyn Oral)

小細胞肺がん (1stライン　メンテナンス療法) / IMforte試験

Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial
6月2日（月）
Abstract 8006 (Lung Oral)

小細胞肺がん (2ndライン) / DELLphi-304試験

Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304
6月2日（月）
Abstract LBA8008 (Lung Oral)

EGFR陽性 非小細胞肺がん (2ndライン） / SACHI試験

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study
6月1日（日）
Abstract LBA8505 (NSCLC Oral)

メラノーマ (術後補助療法) / EORTC-2139-MG試験 & Columbus-AD試験

Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation
6月3日（火）
Abstract LBA9501 (Melanoma Oral)